argenex (ARGX) Stock Forecast & Price Target

argenex
Bull Case

Here are some ways that investors could benefit from investing in argenx SE:

• argenx SE recently completed the acquisition of Forte Biosciences, adding FB102, a first-in-class anti-CD122 antibody, to its immunology pipeline, which expands the company's portfolio of differentiated medicines and offers potential to address multiple autoimmune diseases.
• Wall Street sentiment has shifted significantly in favor of the stock, with UBS Group upgrading argenx SE from a neutral to a buy rating and raising its price target to $1,400.00, while Wells Fargo & Company also lifted its target to $1,415.00, reflecting strong institutional confidence in the company's growth trajectory.
• The company demonstrated strong financial performance in its most recent quarterly results, reporting earnings per share of $7.32, which significantly exceeded the analyst consensus estimate of $5.86, and generated revenue of $1.54 billion, surpassing expectations of $1.45 billion.
• argenx SE has achieved a new 52-week high, with the current stock price standing at $1,028.51, indicating strong momentum and market interest as the stock trades well above its 50-day moving average of $910.13.
• Analysts project substantial long-term growth potential for the company's lead product, Vyvgart, with UBS Group estimating peak sales of $20 billion, suggesting that the current valuation may not fully capture the future revenue upside from this FcRn antagonist.